These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 31915365)

  • 21. Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure.
    Hutchison CA; Plant T; Drayson M; Cockwell P; Kountouri M; Basnayake K; Harding S; Bradwell AR; Mead G
    BMC Nephrol; 2008 Sep; 9():11. PubMed ID: 18808676
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Measurement of free light chains with assays based on monoclonal antibodies.
    Te Velthuis H; Drayson M; Campbell JP
    Clin Chem Lab Med; 2016 Jun; 54(6):1005-14. PubMed ID: 27010775
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Method comparison of four clinically available assays for serum free light chain analysis.
    Fleming CKA; Swarttouw T; de Kat Angelino CM; Jacobs JFM; Russcher H
    Clin Chem Lab Med; 2019 Dec; 58(1):85-94. PubMed ID: 31730518
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Heavy/light chain assay in the monitoring of multiple myeloma.
    Ting HY; Sthaneshwar P; Bee PC; Shanmugam H; Lim M
    Pathology; 2019 Aug; 51(5):507-511. PubMed ID: 31253381
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of a new free light chain ELISA assay: bringing coherence with electrophoretic methods.
    Jacobs JFM; de Kat Angelino CM; Brouwers HMLM; Croockewit SA; Joosten I; van der Molen RG
    Clin Chem Lab Med; 2018 Jan; 56(2):312-322. PubMed ID: 28771430
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical comparison of new monoclonal antibody-based nephelometric assays for free light chain kappa and lambda to polyclonal antibody-based assays and immunofixation electrophoresis.
    Hoedemakers RM; Pruijt JF; Hol S; Teunissen E; Martens H; Stam P; Melsert R; Te Velthuis H
    Clin Chem Lab Med; 2011 Nov; 50(3):489-95. PubMed ID: 22098433
    [TBL] [Abstract][Full Text] [Related]  

  • 27. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders.
    Dispenzieri A; Kyle R; Merlini G; Miguel JS; Ludwig H; Hajek R; Palumbo A; Jagannath S; Blade J; Lonial S; Dimopoulos M; Comenzo R; Einsele H; Barlogie B; Anderson K; Gertz M; Harousseau JL; Attal M; Tosi P; Sonneveld P; Boccadoro M; Morgan G; Richardson P; Sezer O; Mateos MV; Cavo M; Joshua D; Turesson I; Chen W; Shimizu K; Powles R; Rajkumar SV; Durie BG;
    Leukemia; 2009 Feb; 23(2):215-24. PubMed ID: 19020545
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Analytical Criticalities Associated to Different Immunological Methods for Serum Free Light Chain Detection in Plasma Cell Dyscrasias: A Description of Particular Clinical Cases.
    Sabatino R; Perrone A; Cuomo M; Liotti S; Barchiesi V; Cantile M; Cavalcanti E
    Int J Mol Sci; 2017 Apr; 18(4):. PubMed ID: 28417905
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of Long-Term Storage on Serum Free Light Chain Stability.
    Hörber S; Klein R; Peter A
    Clin Lab; 2019 May; 65(5):. PubMed ID: 31115238
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of the serum free light chain (sFLC) analysis in prediction of response in symptomatic multiple myeloma patients: rapid profound reduction in involved FLC predicts achievement of VGPR.
    Hansen CT; Pedersen PT; Nielsen LC; Abildgaard N
    Eur J Haematol; 2014 Nov; 93(5):407-13. PubMed ID: 24809596
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of Freelite™ and N Latex serum free light chain assays in subjects with end stage kidney disease on haemodialysis.
    Kennard A; Hawley C; Tate J; Klingberg S; Pretorius C; Hutchison C; Mollee P
    Clin Chem Lab Med; 2016 Jun; 54(6):1045-52. PubMed ID: 26684350
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diagnostic performance of quantitative kappa and lambda free light chain assays in clinical practice.
    Katzmann JA; Abraham RS; Dispenzieri A; Lust JA; Kyle RA
    Clin Chem; 2005 May; 51(5):878-81. PubMed ID: 15774572
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of the Impact of Renal Failure on Correlation and Concordance Between 2 Free Light Chain Assays.
    Moreau C; Autier B; Cavey T; Rouger E; Norwood J; Bendavid C; Escoffre M; Sébillot M; Decaux O
    Clin Lymphoma Myeloma Leuk; 2016 Dec; 16(12):693-704. PubMed ID: 27618362
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum free light chains: diagnostic and prognostic value in multiple myeloma.
    Sthaneshwar P; Nadarajan V; Maniam JA; Nordin N; Gin Gin G
    Clin Chem Lab Med; 2009; 47(9):1101-7. PubMed ID: 19728852
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reference intervals and diagnostic ranges for serum free κ and free λ immunoglobulin light chains vary by instrument platform: Implications for classification of patient results in a multi-center study.
    Cotten SW; Shajani-Yi Z; Cervinski MA; Voorhees T; Tuchman SA; Korpi-Steiner N
    Clin Biochem; 2018 Aug; 58():100-107. PubMed ID: 29885308
    [TBL] [Abstract][Full Text] [Related]  

  • 36. N Latex FLC serum free light-chain assays in patients with renal impairment.
    Jacobs JF; Hoedemakers RM; Teunissen E; Te Velthuis H
    Clin Chem Lab Med; 2014 Jun; 52(6):853-9. PubMed ID: 24406282
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of Free Light Chain Assays:  Freelite and N Latex in Diagnosis, Monitoring, and Predicting Survival in Light Chain Amyloidosis.
    Mahmood S; Wassef NL; Salter SJ; Sachchithanantham S; Lane T; Foard D; Whelan CJ; Lachmann HJ; Gillmore JD; Hawkins PN; Wechalekar AD
    Am J Clin Pathol; 2016 Jul; 146(1):78-85. PubMed ID: 27353767
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system.
    Snozek CL; Katzmann JA; Kyle RA; Dispenzieri A; Larson DR; Therneau TM; Melton LJ; Kumar S; Greipp PR; Clark RJ; Rajkumar SV
    Leukemia; 2008 Oct; 22(10):1933-7. PubMed ID: 18596742
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma.
    Dispenzieri A; Kyle RA; Katzmann JA; Therneau TM; Larson D; Benson J; Clark RJ; Melton LJ; Gertz MA; Kumar SK; Fonseca R; Jelinek DF; Rajkumar SV
    Blood; 2008 Jan; 111(2):785-9. PubMed ID: 17942755
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of 2 Free Light Chain Assays: Performance of the Free Light Chain Ratio as a Risk Factor for MGUS Progression.
    Wang Q; Andress BD; Pazdernik VMK; Larson DR; Coker JD; Dasari S; Rajkumar V; Dispenzieri A; Murray DL; Willrich MAV
    Clin Chem; 2024 Oct; 70(10):1268-1278. PubMed ID: 39206639
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.